Fig. 3.

Representative Kaplan-Meier plots of median-split gene expression of methylxanthine receptors and metabolizing enzymes from breast carcinomas predicting PFS and OS with regard to steroid receptor status. High expression levels of PDE1A were associated with poorer outcomes of lower PFS (a) and high expression levels of PDE1A and PDE1B were associated with poorer outcomes of lower OS (b, c) of ER− breast carcinomas. High expression levels of PDE1A and low expression of CYP3A4 were associated with poorer outcomes of lower PFS (d, g), and low expression levels of PDE4A and CYP2E were associated with poorer outcomes of lower OS (e, f) of ER− breast carcinomas. High expression levels of PDE1A were associated with poorer outcomes of lower OS (h), and low expression levels of PDE4A were associated with poorer outcomes of lower PFS and OS (i, j) of PR− breast carcinomas. Low expression levels of CYP2E were associated with poorer outcomes of lower OS (k) of PR+ breast cancer